<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02748434</url>
  </required_header>
  <id_info>
    <org_study_id>H16-01025</org_study_id>
    <nct_id>NCT02748434</nct_id>
  </id_info>
  <brief_title>Glucose Variability in Subclinical Hypertrophy</brief_title>
  <official_title>Glucose Variability in Subclinical Hypertrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of insulin absorption at sites affected by clinically apparent lipohypertrophy
      through short-term continuous glucose monitoring has shown inconsistent results and it is yet
      unknown how or if subclinical lipohypertrophy affects absorption. In this study investigators
      propose to enroll at least 20 people who participated in phase 1 and who were determined to
      have subclinical lipohypertrophy to examine the correlation between glycemic control and
      amount of insulin injected in subclinical hypertrophic areas using capillary blood glucose
      and continuous glucose monitoring.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized and data interpreters will be blinded to two alternating six-day
      protocols where the patients will be advised verbally and by written instruction to inject
      insulin in sites of subclinical lipohypertrophy or normal subcutaneous tissue. Patients will
      be asked to monitor and record their capillary blood glucose with meals and prior to bedtime
      using their own capillary blood glucose monitor. A trained research nurse at the Diabetes
      Centre will instrument each patient with an iPro 2 glucose sensor (Medtronic Canada). These
      sensors continuously measure blood glucose for periods of up to 7 days. A trained nurse will
      clean the skin with a superficial disinfectant and a small catheter will be inserted in the
      subcutaneous tissue at a non-lipohypertrophic site. The catheter will then be attached to a
      glucose sensor. Patients will wear this sensor for two periods of 6 days each at different
      sites. At the end of each of the two six day periods, the sensor will be removed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood glucose levels</measure>
    <time_frame>Continuously for 12 days</time_frame>
    <description>iPro2 Continuous Blood Glucose Monitor</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Lipohypertrophy</condition>
  <arm_group>
    <arm_group_label>Lipohypertrophy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants inject their insulin into the abdomen into areas of lipohypertrophy that were identified by ultrasound in Phase 1 of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Subcutaneous Tissue</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants inject their insulin into the abdomen into areas with normal subcutaneous tissue.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lipohypertrophy</intervention_name>
    <arm_group_label>Lipohypertrophy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Subcutaneous Tissue</intervention_name>
    <arm_group_label>Normal Subcutaneous Tissue</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participation in phase 1

          -  Type 1 or Type 2 diabetes for at least 2 years

          -  Using insulin to manage diabetes

          -  At least 19 years of age

        Exclusion Criteria:

          -  Taking insulin secretagogues (gliclazide, glyburide, glipizide

          -  Taking other injectable diabetes medications (i.e. liraglutide, Victoza)

          -  Taking systemic steroids (e.g. prednisone)

          -  Not fluent in speaking and writing English (unless accompanied by a translator)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Graydon Meneilly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jordanna Kapeluto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Breay Paty, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boris Feldman</last_name>
    <phone>604-875-5115</phone>
    <email>boris.feldman@vch.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gerontology Research Lab</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boris Feldman</last_name>
      <phone>604-875-5115</phone>
      <email>boris.feldman@vch.ca</email>
    </contact>
    <investigator>
      <last_name>Graydon S Meneilly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital Diabetes Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boris Feldman</last_name>
      <phone>604-875-5115</phone>
      <email>boris.feldman@vch.ca</email>
    </contact>
    <investigator>
      <last_name>Graydon S Meneilly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2016</study_first_submitted>
  <study_first_submitted_qc>April 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2016</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Graydon Meneilly</investigator_full_name>
    <investigator_title>Professor, UBC Department of Medicine</investigator_title>
  </responsible_party>
  <keyword>iPro2 Continuous Blood Glucose Recorder</keyword>
  <keyword>Subclinical</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

